Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

A legfontosabb adatok

Ki végzi
Novoic Limited
Hol
Santa Ana (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Résztvevők
42 fő vett részt
Kezdés
2021. jan. 21.
Befejezés
2024. máj. 28.
A vizsgálat típusa
Megfigyeléses, 4 csoport
A regiszteradat frissítve
2024. június 14.
Miért állt le
Study only continued to 2 year follow-up.

Ki vehet részt

Életkor
50 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek
A regiszter összes feltétele (3)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Subjects are fully eligible for and have completed the AMYPRED-US (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study; (See https://clinicaltrials.gov/ct2/show/NCT04928976)
  • Subject consents to take part in FUTURE extension study

Ki nem vehet részt

  • Subject hasn't completed the full visit day in the AMYPRED-US study

Helyszínek itt: Egyesült Államok

  • Syrentis Clinical ResearchSanta Ana, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5) between baseline and +12 month follow up across all four Arms, as measured by the coefficient of individual agreement (CIA) between the change in PACC5 and the corresponding regression model, trained on baseline speech data to predict it. Secondary objectives include (1) evaluating whether similar algorithms can predict change in PACC5 between baseline and +12 month follow up in the cognitively normal (CN) and MCI populations separately; (2) evaluating whether similar algorithms trained to regress against PACC5 scores at baseline, still regress significantly against PACC5 scores at +12 month follow-up, as measured by the coefficient of individual agreement (CIA) between the PACC5 composite at +12 months and the regression model, trained on baseline speech data to predict PACC5 scores at baseline; (3) evaluating whether similar algorithms can classify converters vs non-converters in the cognitively normal Arms (Arm 3 + 4), and fast vs slow decliners in the MCI Arms (Arm 1 + 2), as measured by the Area Under the Curve (AUC) of the receiver operating characteristic curve, sensitivity, specificity and Cohen's kappa of the corresponding binary classifiers. Secondary objectives include the objectives above, but using time points of +24 months and +36 months; and finally to evaluate whether the model performance for the objectives and outcomes above improved if the model has access to speech data at 1 week, 1 month, and 3 month timepoints.

A vizsgálat 4 csoportja

  • Arm 1: MCI amyloid positive

    * Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's * Positive amyloid PET or amyloid CSF status. * MMSE 23-30 (inclusive)

  • Arm 2: MCI amyloid negative

    * Non-AD Mild Cognitive Impairment (MCI) * Negative amyloid PET or amyloid CSF status. * MMSE 23-30 (inclusive)

  • Arm 3: CN amyloid positive

    * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline * Positive amyloid PET or amyloid CSF status. * MMSE 26-30 (inclusive)

  • Arm 4: CN amyloid negative

    * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline * Negative amyloid PET or amyloid CSF status. * MMSE 26-30 (inclusive)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting - AMYPRED-US FUTURE Extension Study.
A regiszteradat frissítve
2024. június 14.